Aura Biosciences, Inc.
NASDAQ:AURABiotechnology
-$0.09 today
- Market cap
- $743.09M
- Beta
- 0.39
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$1.67
Volume 0.69M
Average 0.52M
AURA Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Aura Biosciences, Inc.NASDAQ: AURA
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $274K fell 5.8% year over year, ahead of the -7.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.7% from the prior quarter. Over 3 fiscal years it compounded at -1.4% a year.
Context
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -5.8% holds above the trailing-twelve-month pace of -7.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 1.13M USD
- Year-over-year change
- -7.7%
- 4-year CAGR
- +8.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.13M | -7.7% |
| FY2024 | 2024-12-31 | 1.22M | -5.6% |
| FY2023 | 2023-12-31 | 1.3M | +10.0% |
| FY2022 | 2022-12-31 | 1.18M | +41.6% |
| FY2021 | 2021-12-31 | 831K | — |
Depreciation & Amortization vs competitors
How AURA compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -7.9% is the 7th highest of 11, against a peer median of -1.7%.
- Over three fiscal years its annual growth of -1.4% compares with a peer median of +20.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.94M USD | -7.1% | -22.5% | 4.4% | |
| LTM Sep 2026 | $3.76M USD | +35.4% | +67.3% | — | |
| LTM Mar 2026 | $2.45M USD | +41.2% | -1.9% | 32.1% | |
| FY2025 | $2.33M USD | +47.9% | +73.6% | 35.8% | |
| LTM Mar 2026 | $2.07M USD | -23.3% | +70.7% | 46.4% | |
| LTM Mar 2026 | $1.11M USD | -7.9% | -1.4% | — | |
| LTM Mar 2026 | CHF 580.43K CHF | +27.3% | +22.2% | 115.2% | |
| LTM Mar 2026 | $511.27K USD | -107.2% | +20.3% | 0.8% | |
| LTM Mar 2026 | $287K USD | -146.9% | — | — | |
| LTM Mar 2026 | $119.64K USD | +3.7% | -17.0% | 35.9% | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $79K USD | -59.1% | -20.8% | 1.1% |
| Peer median (excluding AURA) | — | -1.7% | +20.3% | 34.0% | |
Competitors are the stored peer set for AURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (35.25M) | (58.76M) | (76.41M) | (86.92M) | (106.19M) |
| Depreciation & Amortization | 831K | 1.18M | 1.3M | 1.22M | 1.13M |
| Deferred Income Tax | 14K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.31M | 6.41M | 8.77M | 11.72M | 14.32M |
| Change in Working Capital | (315K) | (3.1M) | 4.44M | (2.64M) | 5.97M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.05M | 340K | (1.04M) | 482K | (846K) |
| Other Working Capital | (1.37M) | (3.44M) | 5.48M | (3.12M) | 6.82M |
| Other Non-Cash Items | 4K | (325K) | (1.95M) | (3.19M) | 32K |
| Operating Cash Flow | (32.41M) | (54.6M) | (63.85M) | (79.81M) | (84.74M) |
| Capital Expenditures | (2.13M) | (1.09M) | (709K) | (1.25M) | (447K) |
| Acquisitions (Net) | 0 | 66.78K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (119.78M) | (233.65M) | (59.11M) | (83.96M) |
| Sales of Investments | 0 | 53.01M | 120.4M | 129.18M | 120M |
| Other Investing Activities | 0 | (66.78K) | 0 | 0 | 0 |
| Investing Cash Flow | (2.13M) | (67.87M) | (113.96M) | 68.82M | 35.6M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 78.7M | 8.55M | 3.17M | 1.6M | 77.16M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 334K | 430K | 1.5M | 0 | 0 |
| Financing Cash Flow | 166.26M | 95.63M | 97.29M | 1.6M | 77.16M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (186K) |
| Net Change in Cash | 131.72M | (26.84M) | (80.52M) | (9.39M) | 27.82M |
| Free Cash Flow | (34.54M) | (55.7M) | (64.56M) | (81.06M) | (85.19M) |
Aura Biosciences, Inc.
NASDAQ:AURA
Intrinsic Alpha fair value
Locked
Current Price
$7.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.